The growing awareness of AMD and the increasing geriatric population are anticipated to exhibit more opportunities for the growth of the Macular Degeneration Treatment market. Moreover, as per the Community Eye Health Journal published in 2014 by the London School of Hygiene and Tropical Medicine, nearly 196 million people are estimated to suffer from Macular Degeneration Treatment by 2020 worldwide.
The global market for Macular Degeneration Treatments is expected to grow at a CAGR of approximately 7.3% during the forecast period.
Regionally, the Americas Macular Degeneration Treatment market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global Macular Degeneration Treatment market owing to the increasing cases of macular degeneration and growing health concerns. According to the Centers for Disease Control and Prevention (CDC), it was estimated that about 1.8 million people are suffering from Macular Degeneration Treatments in America. Moreover, nearly 7.3 million people are at a significant risk of vision loss due to AMD.
Treatments targeting biochemical pathways implicated in the macular degeneration pathophysiology of ARMD are being tested actively in clinical trials
The global Macular Degeneration Treatment market is segmented by type, drug, route of administration, treatment, and end-user.
On the basis of type, the global Macular Degeneration Treatment market is segmented into dry Macular Degeneration Treatment and wet Macular Degeneration Treatment.
On the basis of drug, the global Macular Degeneration Treatment market is segmented into Eylea, Visudyne, Lucentis, Avastin, and others.
On the basis of route of administration, the global Macular Degeneration Treatment market is segmented into intravenous, intravitreal, and others.
On the basis of treatment, the global Macular Degeneration Treatment market is segmented into medications, devices, surgery, and others. The medication segment is further classified into anti-VEGF drugs, blood vessel growth inhibitors, vitamins, dietary supplements, and others. The devices segment is classified into corrective lenses, glasses, contact lenses, and others.
On the basis of end-user, the global Macular Degeneration Treatment market is segmented into hospitals and diagnostic centers, clinics, academic research institutes, pharmaceutical and biotechnology companies, and others.
Some of the key players in the global Macular Degeneration Treatment market are Novartis International AG (Switzerland), Bayer AG (Germany), Acucela Inc. (U.S.), Neurotech Pharmaceuticals Inc. (U.S.), Ophthotech Corporation (U.S.), GlaxoSmithKline Plc (U.S.), Alimera sciences Inc. (U.S.), StemCell Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron Pharmaceutical Inc. (U.S.), Allergan Plc (Ireland), Adverum Biotechnologies Inc. (U.S.), Gilead Sciences Inc. (U.S.), Iconic Therapeutics Inc. (U.S.), Lpath Inc. (U.S.), OHR Pharmaceutical Inc. (U.S.), Bausch + Lomb (U.S.), Opthea Limited (Canada), PanOptica, Inc. (U.S.), Pfizer Inc. (U.S.), Neurotech Pharmaceuticals, Inc. (U.S.), Promedior, Inc. (U.S.), QLT Inc. (Canada), Quark (U.S.), Resolvyx Pharmaceuticals Inc. (U.S.), RXi Pharmaceuticals Inc. (U.S.), Sagent Pharmaceuticals, Inc. (U.S.), Alcon Vision Care (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Sanwa Kagaku Kenkyusho (Japan), and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com